Ioannis Vathiotis

Lung cancer is, in part, a hereditary disease. Excited to share our perspective on the incorporation of germline testing in patients with lung cancer @triparnasen @fred_hirsch @SyrigosKostas @elekapLC @LancetRespirMed thelancet.com/journals/lanre….

Congratulations to David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology) @YaleMed, on being selected by the @AACR for its 2026 James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research. bit.ly/4vslGrI

Το ΣΟΚ της διάγνωσης — η στιγμή που όλα αλλάζουν. Το 2ο τεύχος του «ΠΝΟΕΣ» μόλις κυκλοφόρησε! Διαβάστε το τεύχος → isu.pub/2yEmcAT #Pnoes #Elekap #TogetherWeCan #PnoesMagazine #Oncology #healthandlifestylemagazine

🫁 PNOES, the new magazine by ELEKAP, is here — a space where science meets empathy, and stories of strength and healing inspire us all to breathe, connect and live better. Discover the first issue : isu.pub/SGVFwcT #PNOESMagazine

There’s nothing like Cedar Street in the fall. @YaleMed

Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer @NatureGenet @OncoAlert #SpatialMedicine #lungcancer #PrecisionMedicine nature.com/articles/s4158…

Mini Review: Histologic Transformation in Cancer: The Path for Clinical Translation doi.org/10.1158/2159-8… By @IVathiotis, @AvisekBanerje11, @triparnasen, and colleagues at @OhioStateMedOnc @IcahnMountSinai @uoaofficial

#WCLC25 Presidential FLAURA2 OS in 1L EGFR+ NSCLC: - mOS 47.5m v 37.6m (HR 0.77 p=0.02) - duration of osi 30.5m on osi+chemo v 21.2m osi- combo delays acq resistance? - 72% got 2L chemo- does this add ~9m? - all subgrps benefit (?BM, ?co-mtns) Congrats @dplanchard @iaslc #LCSM

FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx: -Intensification for all pts? Benefit in some subgroups only (Brain) -Chemo or ami for intensification?toxicity QoL, relevant for decisions -Cost -Is Osi alone no more valid? #WCLC2025

🧵(1/3) Thrilled to share our timely review just published in @CD_AACR: Histologic Transformation in #Cancer: The Path for Clinical Translation. This complex and dynamic adaptive process poses major #clinical #challenges in #lungcancer and #prostatecancer. #CellPlasticity #DrugResistance #CancerResearch #LCSM #LUAD #SCLC #LUSC #NEPC #PDAC @oncodaily @OncLive @OncoAlert @OSUWexMed @OhioStateMedOnc @OhioState @OhioStateWIMS @LUNGevity @lcrf_org @lcfamerica @LiveLung1 @IASLC @PCR_News @AACR @ElizSMcKenna

Excited to share our review on "Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity" in @JTOonline. We examine how #LUAD transforms into #SCLC or #LUSC under treatment pressure as a key factor in #resistance, and unpack the #genetic, #epigenetic, and #immune programs that drive this #evolution. Understanding these histologic switches opens the way for new #therapeutictargets to prevent or stop tumor escape. So proud to have collaborated with an amazing and fun team of friends and collaborators- @AvisekBanerje11, @IVathiotis, @fred_hirsch, @SyrigosKostas, @drshieldsmd, @UtsavSen10, Drs. Raj Veluswamy, Xuejun Wang, Debdatta Halder. @IcahnMountSinai @OSUCCC_James @IASLC @Pelotonia @OncLive @oncodaily @LiveLung1 @lcrf_org @LUNGevity @SclcSMASHERS @lcfamerica #SCLC #NSCLC #lungcancer #translationalresearch #CancerResearch #lineageplasticity #onegoal #EndingCancer jto.org/article/S1556-…

Great publication paving the way into the future! Proud to be co-author! Congrats to Dr. Sen the group! Just published in JTO.

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO

@triparnasen is an excellent candidate for the @IASLC Board of Directors (Basic Science). She has all the qualities and demeanour to make the difference. She is a driven scientist and great collaborator!

I am truly thrilled and humbled to be nominated as a candidate for the @IASLC Board of Directors (Basic Science). @IASLC has been my professional home for nearly a decade—a place that has shaped my journey as a #scientist, #mentor, and #collaborator. I have met some of the most inspiring scientists and mentors through @IASLC. To be considered for this role is both a personal milestone and a profound opportunity to give back to the global #lungcancer community. With deep gratitude to those who have supported my path (@fred_hirsch @JhanelleGray), I am committed to advancing IASLC's mission to advance #lungcancer #research, #education, and #multidisciplinary partnerships. I am passionate about and will work towards: 🔬 Elevating basic and translational science 🌱 Empowering the next generation of investigators 🤝 Strengthening global collaborations 📚 Expanding access to education and mentorship 💡 Building new bridges for funding and innovation Voting is open April 17 – May 22 for all IASLC members. Look out for a personalized ballot from: noreply@directvote.net 🔗 Learn more about Basic Science Candidates (including me): iaslc.org/2025-basic-sci… Let us shape the future of lung cancer care together 💙. #IASLC #LungCancerResearch #TranslationalScience #GlobalOncology #Leadership #ThoracicOncology #IASLC2025 #LCSM @IcahnMountSinai @TischCancer @lcfamerica @lcrf_org @LUNGevity @LiveLung1 @oncodaily @lcsmchat

Phase I/II SOHO-01: BAY 2927088 in HER2m NSCLC. In HER2i-naive (cohort D): ORR 70.5%, DoR 8.7 mo. EGFRi-like AEs (rash, diarrhea). Busy Ph3 landscape: TKIS (SOHO-02, WU-KONG28 FURMO-004) or TKIs + ChT (REZILIENT3) vs SoC in 1L HER2m NSCLC #ESMOAmbassadors #ELCC25 @myESMO

New test developed for #breastcancer by @RimmPathology at @YaleMed may allow for more personalized #lungcancer therapy. “The way we did this measurement was by using cell line standards, which is a bit novel,” Dr. Rimm tells @HemOncToday. @YaleCancer bit.ly/3Z3FqU8

Retrospective report in European Journal of Cancer on #EGFR mutant NSCLC transformed to #SCLC. Post transformation, 93% were DLL3 positive. Are BiTEs like tarlatamab viable options here? No clear current standard (chemo, chemo + TKI, chemo + IO). ejcancer.com/article/S0959-…

Another proof of concept that adjuvant component of perioperative IO is NOT for all: NOT adding benefit to patients who achieve PCR and NOT enough for patients without MPR/PCR…Room for deescalation for PCR patients and for escalation strategies in non-PCR/ MPR?? Congrats @RobertoFerrara_ and all authors for this insight, one thing is for sure, perioperative IO will not be as we know today in one year from now #some #lcsm @OncoAlert @OncoViews @OncBrothers @VJOncology @HeSMO_X

Stage III ALK+ NSCLC: consolidation ALK TKI v Durva v Obs @JTOonline: -67pts, ALKi=15 Durva=30 obs=22 -mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001) Small n, but useful @OncoAlert @AminNassarMD #LCSM jto.org/article/S1556-…

Amazing Presidential Symposium @myESMO. Eyes to the future, biomarkers in the spotlight: precision oncology, AI, organ preservation approaches and emerging therapeutic targets. The future is bright - collaboration and access will be key!